Virobay
Discovering the posibilities
2006 - Founded as an anti-viral drug discovery and development company
2007 - Filed IND and initiated Phase I trial with lead protease inhibitor as an oral treatment for Hepatitis C
2007 – In-licensed cathepsin protease inhibitor assets; including VBY-129, a selective cathepsin S inhibitor which completed phase 1 clinical development for psoriasis
2008 – Virobay assets solve the chemical challenge of cathepsin inhibitor design; multiple orally bioavailable development candidates are poised for Phase I
Pipeline
Virobay is investigating promising new approaches for the treatment of hepatitis C, autoimmune diseases, neuropathic pain, liver injury and cancer.
(Clinical Candidate) |
||||
|---|---|---|---|---|
| Hepatitis C Protease Inhibitors | ||||
| VBY-376 | X | |||
| VBY-106 | X | |||
| Autoimmune Diseases | ||||
| VBY-129 | X | |||
| VBY-891 | X | |||
| VBY-036 | X | |||
| Neuropathic Pain | ||||
| VBY-891 | X | |||
| VBY-036 | X | |||
| VBY-285 | X | |||
| Oncology | ||||
| VBY-825 | X | |||
| Liver Fibrosis | ||||
| Multiple compounds | X | |||
